![](https://investorshub.advfn.com/uicon/78991.png?cb=1630499252)
Tuesday, April 18, 2023 8:07:20 AM
![smile](/images/emoticon01.gif)
CNTX chart
Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?
"We hope not." Richard Dennis
Recent CNTX News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/24/2024 09:07:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/24/2024 08:55:48 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/12/2024 08:04:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 11:33:59 AM
- Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95 • GlobeNewswire Inc. • 07/10/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 11:50:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 11:34:52 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/03/2024 04:15:21 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/31/2024 08:06:51 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/24/2024 08:15:19 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/24/2024 11:31:07 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/10/2024 08:00:06 PM
- Context Therapeutics Reports First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 05/08/2024 08:06:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:03:39 PM
- Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 • GlobeNewswire Inc. • 05/02/2024 11:31:53 AM
- Context Therapeutics Announces $100 Million Private Placement • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers • GlobeNewswire Inc. • 04/01/2024 11:30:00 AM
- Context Therapeutics Reports Full Year 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/21/2024 11:43:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 12:30:51 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/07/2024 09:24:50 PM
- Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results • GlobeNewswire Inc. • 11/09/2023 09:15:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:04:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 01:04:29 PM
- Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76 • GlobeNewswire Inc. • 10/31/2023 01:00:00 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM